Researchers at Strathclyde University in the UK have shown that galegine, a natural product from the plant Galega officinalis can reduce body weight in normal and obese mice.
Galegine is orally active, causing a marked and long-lasting reduction in body weight, as well as a lowering of blood glucose levels. The researchers have synthesised a number of galegine derivatives, and these have been shown to have similar weight-reducing effects upon oral administration.
Studies of the mode of action suggest that galegine and active analogues act directly on fat metabolism by activating AMP-activated protein kinase. Independent in vitro toxicity testing of the active analogues raised no concerns about possible mutagenicity, cytotoxicity or non-specific pharmacological effects.
The researchers believe the compounds could be used in anti-obesity drugs and in the treatment of Type II diabetes. The technology has US patent protection.
Contact is welcomed from organisations interested in developing, licensing or exploiting this technology.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.